The EGFR- and KRAS wild type adenocarcinomas had additionally significantly more arm-wise aberrations compared with the EGFR- and KRAS-mutant lung adenocarcinomas, suggesting that tumors without mutational activation of these oncogenic pathways are more driven by copy number aberrations than of point mutations. The gene discussed is EGFR; the disease is lung adenocarcinoma.